This testing covers nuclear genes associated with inherited mitochondrial diseases organized as an overall mitochondrial disease nuclear gene panel and three phenotype-specific subpanels.
- Full Mitochondrial Disease Nuclear Gene Panel – 390 genes
- Mitochondrial Encephalopathy/Leigh Disease – 119 genes
- mtDNA Depletion and Deletion Panel – 21 genes
- Progressive External Ophthalmoplegia (PEO)/Optic Atrophy – 77 genes
A complete list of the genes included in each panel can be found on our gene list.
Please contact us if you wish to order testing for a single gene or a custom set of genes from the mitochondrial disease panel.
The panel and subpanels are run on an augmented exome backbone. This test is based on the Agilent CRE V1.0, and then was supplemented with custom probes for regions with consistently poor coverage. Exome reanalysis is available on a research basis with patient consent.
Not all exons are captured equally well, resulting in some regions that are consistently under represented (>99% of targeted regions will have >30X read depth for coding bases; >99.7% at >20X), with 20X coverage as our minimal quality standard for reporting. Sanger sequencing will be used to supplement NGS for targets with <20X read depth for any coding base, and/or for variant validation, except for a small number of genes indicated on the gene list. Copy Number Variation (CNV) analysis is not routinely performed; we do however manually inspect NGS data for possible CNVs by assessing read depth variation in genes with one clinically significant variant. While we are not able to assess the sensitivity of this method, we have successfully identified many CNVs with this approach. Our capture methodology along with NGS does not detect large deletions, insertions, chromosomal abnormalities or large rearrangements. We continue to refine our approaches to CNV analysis and updates will be posted here. Please note that while the capture method targets the mitochondrial genome, we have not yet validated this assay for mtDNA variants; once validated, we will post an update here. Please feel free to contact us if you have questions about coverage for possible variants in any genes, generally or in the context of a specific patient.